Sign inJoin waitlistJoin the waitlist

Robert Orlowski

SCB Co-Leader · University of Texas M D Anderson Cancer Center

Credentials: · · · · ·

History

University of Texas M D Anderson Cancer Center
Present
University of Texas M D Anderson Cancer Center
Present

Medical Oncology
1994–1998
Johns Hopkins University School of Medicine
1995–1998
Internal Medicine
Washington University School of Medicine
1991–1994
Medical Oncology
1992–1994
Yale Univ Sch of Med
1987–1991

Research

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Review · The Lancet Oncology · 2016 · 2,602 citations
A phase 2 study of bortezomib in relapsed, refractory myeloma
New England Journal of Medicine · 2003 · 2,206 citations
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
Journal of Clinical Oncology · 2015 · 1,739 citations

Sheeba Thomas
103 papers
HL
Hans Lee
95 papers · 2 as a fellow
Muzaffar Qazilbash
91 papers
Krina Patel
85 papers
DW
Donna Weber
83 papers
Richard Champlin
81 papers
Qaiser Bashir
80 papers
EM
Elisabet Manasanch
61 papers
Yago Nieto
57 papers
JS
Jatin Shah
55 papers
Elizabeth Shpall
52 papers
Partow Kebriaei
51 papers

Grants

Role of Heat Shock Protein 70 as a Mediator and Therapeutic Target in T-Cell Lymphomas
National Cancer Institute · R01
Contact PI · $2.4M · University of Tx Md Anderson Can Ctr
2022–2027
The University of Texas MD Anderson Cancer Center Support Grant (CCSG)
National Cancer Institute · P30
Project lead · $146.9K · University of Tx Md Anderson Can Ctr
1996–2026
Proteasome Assembly Chaperones in Sensitivity and Resistance to Proteasome Inhibitors
National Cancer Institute · R01
Contact PI · $1.8M · University of Tx Md Anderson Can Ctr
2016–2023
Role of TJP1 in Sensitivity and Resistance to Proteasome Inhibitors in Myeloma
National Cancer Institute · R01
Contact PI · $1.8M · University of Tx Md Anderson Can Ctr
2015–2021

Clinical trials

Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma
Principal investigator · Recruiting · Phase 1, Phase 2
M.D. Anderson Cancer Center
2024–2029
A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma
Principal investigator · Recruiting · Phase 1
M.D. Anderson Cancer Center
2022–2027
Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis
Principal investigator · Terminated · Phase 1
M.D. Anderson Cancer Center
2014–2016
Intervention for Symptom Burden During Maintenance Therapy for Multiple Myeloma
Principal investigator · Completed · Phase 2
M.D. Anderson Cancer Center
2013–2020